Characteristics of participants with graft failure
| Type of graft failure . | Days posttransplant . | Recipient age (y) . | Donor age (y) . | Sex (D/R) . | TNC cell dose × 108/kg . | DSA . | ABO mismatch . | CMV serostatus (D/R) . | CMV reactivation . | Comments . |
|---|---|---|---|---|---|---|---|---|---|---|
| Primary | 31 | 8.2 | 39 | Female/female | 10.5 | No | None | Positive/negative | No | Discontinued sirolimus for suspected allergy at d +21, treated with high-dose steroids; later developed hypertension and PRES |
| Primary | 26 | 3.8 | 40 | Male/male | 5.6 | No | Major | Negative/positive | Yes | Parainfluenza < d +30 posttransplant |
| Primary | 31 | 16.0 | 38 | Female/male | 3.1 | No | None | Positive/positive | Yes | CMV viremia, MRSA bacteremia Died on d +411 of fungemia after the second transplant |
| Primary | 33 | 5.4 | 31 | Female/female | 5.1 | No | None | Positive/negative | Yes | HSV stomatitis, CMV viremia, Enterobacter bacteremia |
| Secondary | 87 | 15.1 | 35 | Female/male | 4.5 | No | None | Positive/negative | No | None |
| Secondary | 153 | 15.2 | 42 | Female/male | 1.3 | No | Major | Positive/negative | No | Invasive fungal infection (chest), CNS bacteremia, EBV viremia |
| Secondary | 67 | 6.0 | 45 | Male/male | 7.0 | No | None | Positive/negative | No | MRSA, urine BK virus cystitis |
| Secondary | 97 | 14.8 | 16 | Male/male | 23.5 | No | None | Positive/positive | Yes | CMV viremia |
| Type of graft failure . | Days posttransplant . | Recipient age (y) . | Donor age (y) . | Sex (D/R) . | TNC cell dose × 108/kg . | DSA . | ABO mismatch . | CMV serostatus (D/R) . | CMV reactivation . | Comments . |
|---|---|---|---|---|---|---|---|---|---|---|
| Primary | 31 | 8.2 | 39 | Female/female | 10.5 | No | None | Positive/negative | No | Discontinued sirolimus for suspected allergy at d +21, treated with high-dose steroids; later developed hypertension and PRES |
| Primary | 26 | 3.8 | 40 | Male/male | 5.6 | No | Major | Negative/positive | Yes | Parainfluenza < d +30 posttransplant |
| Primary | 31 | 16.0 | 38 | Female/male | 3.1 | No | None | Positive/positive | Yes | CMV viremia, MRSA bacteremia Died on d +411 of fungemia after the second transplant |
| Primary | 33 | 5.4 | 31 | Female/female | 5.1 | No | None | Positive/negative | Yes | HSV stomatitis, CMV viremia, Enterobacter bacteremia |
| Secondary | 87 | 15.1 | 35 | Female/male | 4.5 | No | None | Positive/negative | No | None |
| Secondary | 153 | 15.2 | 42 | Female/male | 1.3 | No | Major | Positive/negative | No | Invasive fungal infection (chest), CNS bacteremia, EBV viremia |
| Secondary | 67 | 6.0 | 45 | Male/male | 7.0 | No | None | Positive/negative | No | MRSA, urine BK virus cystitis |
| Secondary | 97 | 14.8 | 16 | Male/male | 23.5 | No | None | Positive/positive | Yes | CMV viremia |
Graft failure occurred in 8 of the 70 study participants; 4 experienced primary graft failures, and 4 experienced secondary graft failures.
CMV, cytomegalovirus; CNS, coagulase-negative staphylococci; D/R, donor/recipient; DSA, donor-specific antibody; EBV, Epstein-Barr virus; HSV, herpes simplex virus; MRSA, methicillin-resistant Staphylococcus aureus; PRES, posterior reversible encephalopathy syndrome; TNC, total nucleated cell.